[Burkitt's lymphoma in 1985].
Burkitt Lymphoma is a model for either clinical research and fundamental research. Initially described in Africa, it is the most frequent of all childhood Lymphoma. Burkitt Lymphoma allowed in the laboratory to study the virus cancer relationship, the chromosome cancer relationship, the gene and cancer relationship and the oncogene and cancer relationship. This study is made considerably more easy because of the numerous cell lines which were established from malignant cells at different stages of the disease. Patients who have a complete remission of more than 8 months could be considered as cure of the disease. Then, B.L. is also a model for clinical study because we can conclude rapidly the efficacy or not of a new protocol. Since 1980, overall survival in France has moved from 40 to 80%. Chemotherapy alone is responsible for these results either by conventional protocol or in a small % cases by massive therapy followed by autologous bone marrow transplantation.
D000349:Africa; D000367:Age Factors; D000914:Antibodies, Viral / Q000032:analysis; D001402:B-Lymphocytes / Q000276:immunology; D016026:Bone Marrow Transplantation; D002051:Burkitt Lymphoma / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000382:microbiology / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D002460:Cell Line; D002471:Cell Transformation, Neoplastic; D002648:Child; D002901:Chromosomes, Human, 13-15; D002906:Chromosomes, Human, 6-12 and X; D005060:Europe; D004854:Herpesvirus 4, Human; D006801:Humans; D007136:Immunoglobulins / Q000235:genetics; D009857:Oncogenes; D011379:Prognosis; D012737:Sex Factors; D014178:Translocation, Genetic; D014481:United States
D000914:Antibodies, Viral; D007136:Immunoglobulins
Le lymphome de Burkitt en 1985.